ArticleTherapeutic advances in musculoskeletal disease2026
Psoriatic arthritis management: a comparative analysis of PANLAR, EULAR, and GRAPPA treatment recommendations.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis associated with psoriasis, affecting multiple domains, including peripheral joints, axial skeleton, enthesis, dactylitis, and skin. Several multinational organizations, including European Alliance of Associations for Rheumatology (EULAR), Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), and Pan American League of Associations for Rheumatology (PANLAR), have established treatment recommendations to optimize patient care. However, differences may exist in their guidelines, reflecting methodology regional differences, expert consensus, and evolving evidence. Design and objectives: This review compares the treatment recommendations for PsA established by EULAR, GRAPPA, and PANLAR, highlighting similarities, differences, and challenges in achieving standardized treatment strategies worldwide. Methods: A comparative literature review analyzing key aspects of each guideline was performed. A systematic evaluation of the latest three multinational treatment recommendations was conducted, focusing on pharmacological and nonpharmacological management approaches. Differences in treatment sequencing, targeted therapies, and emphasis domains were examined. Results: While all three organizations emphasize a multidisciplinary and personalized approach to PsA treatment, some variations exist in the preferred sequencing of therapies, the role of targeted synthetic disease-modifying antirheumatic drugs, and the approach to extra-musculoskeletal manifestations. PANLAR provides a regional perspective with emphasis on access constraints, EULAR integrates real-world evidence and long-term safety data, and GRAPPA emphasizes domain-based treatment. Conclusion: While PANLAR, EULAR, and GRAPPA guidelines align in core treatment principles, key differences persist, influencing clinical decision-making. Greater international collaboration may enhance the harmonization of treatment recommendations, ensuring optimal patient outcomes globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.